A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia.

C. Flowers,Jennifer R. Brown,H. Rosenthal,W. Stock,H. Katzen,Jonathon B. Cohen,R. Sinha,S. Lakhanpal,J. Leis,E. Waller,D. Jaye
DOI: https://doi.org/10.1016/j.clml.2015.07.640
2015-11-01
Abstract:
What problem does this paper attempt to address?